(19)
(11) EP 2 465 522 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.11.2014 Bulletin 2014/47

(45) Mention of the grant of the patent:
13.08.2014 Bulletin 2014/33

(21) Application number: 12152769.1

(22) Date of filing: 25.03.2008
(51) International Patent Classification (IPC): 
A61K 38/10(2006.01)
A61P 31/00(2006.01)
C07K 14/47(2006.01)
 A61P 29/00(2006.01)
C07K 7/08(2006.01)

(54)

Chemerin-15h and its use for treatment of inflammation and endotoxic shock

Chemerin-15h und seine Verwendung zur Behandlung von Entzündung und Endotoxinschock

Chemerin-15h et son utilisation pour le traitement de inflammation et choc endotoxique

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 22.03.2007 GB 0705488

(43) Date of publication of application:
20.06.2012 Bulletin 2012/25

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08718857.9 / 2131852

(73) Proprietor: Isis Innovation Limited
Summertown, Oxford OX2 7SQ (GB)

(72) Inventors:
  • Greaves, David, R
    Oxford, oxfordshire OX1 3RE (GB)
  • Russ, Andreas
    20253 Hamburg (DE)
  • Cash, Jenna, L.
    Berkshire RG4 8DN (GB)

(74) Representative: Atkinson, Jennifer 
Barker Brettell LLP 100 Hagley Road
Edgbaston Birmingham B16 8QQ
Edgbaston Birmingham B16 8QQ (GB)


(56) References cited: : 
US-A1- 2006 024 750
   
  • ZABEL ET AL: "Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, 2005, pages 34661-34666, XP002486778,
  • WITTAMER ET AL: "The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 9956-9962, XP002310263,
  • WITTAMER ET AL: "Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, 2003, pages 977-985, XP002273639,
  • WITTAMER ET AL: "Neutrophil-mediated maturation of chemerin: A link between innate and adaptive immunity", THE JOURNAL OF IMMUNOLOGY, vol. 175, 2005, pages 487-493, XP002675592,
  • KULIG ET AL: "Staphylococcus aureus-derived staphopain B, a potent cysteine protease activator of plasma chemerin", THE JOURNAL OF IMMUNOLOGY, vol. 178, 15 March 2007 (2007-03-15), pages 3713-3720, XP002487265,
  • ROH ET AL: "Chemerin - a new adipokine that modulates adipogenesis via its own receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 362, August 2007 (2007-08), pages 1013-1018, XP022249546,
  • CASH ET AL: "Synthetic chemerin-derived peptides suppress inflammation through ChemR23", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, April 2008 (2008-04), pages 767-775, XP002675548,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).